Skip to main content
. Author manuscript; available in PMC: 2009 Jun 1.
Published in final edited form as: Clin Gastroenterol Hepatol. 2008 Jun;6(6):661–670. doi: 10.1016/j.cgh.2008.02.033

Figure 5.

Figure 5

Figure 5a. Preferred initial testing strategy when therapy or definitive diagnosis is the model endpoint. Using a Monte Carlo simulation of 100,000 trials, 77% of trials favored DBE as the initial diagnostic strategy. CE was preferred in 9% of simulated trials, while PE was preferred as the initial test in 8%. EN and SBFT accounted for 6% of total trials.

Figure 5b. Preferred initial testing strategy when therapy or definitive diagnosis is the model endpoint and DBE is not available as an initial strategy. Using a Monte Carlo simulation of 100,000 trials, 45% of trials favored CE as the initial diagnostic strategy. PE was preferred in 24% of simulated trials, while EN and SBFT were preferred as the initial test in 16% and 15% of trials respectively.